PTT-936 / Pyrotech Therap - LARVOL DELTA

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=68 | Recruiting | Sponsor: Pyrotech Therapeutics, Inc. | Trial completion date: Feb 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Sep 2027

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Discovery of an orally available and liver-targeted ALPK1 agonist for cancer immunotherapy (AACR 2024) - "Furthermore, PTT-936 does not enhance cytokine elevations induced by checkpoint inhibitors, which have been linked to adverse events (including CRS) observed in clinical combination studies. The dosing frequency of PTT-936 in the upcoming first-in-human clinical trial is carefully designed to prioritize both tolerability and patient compliance."

First-in-human • IO biomarker • Oncology • CD8 • STING

Yanming Biopharma's Class 1 tumor immunotherapy drug with a new mechanism has been approved for clinical trials in China [Google translation] (bydrug.pharmcube.com) - "On March 14, 2025, Beijing Yanming Biotechnology Co., Ltd...announced that PTT-936...has been approved by the U.S. Food and Drug Administration (FDA) for clinical research and has been approved by the China Food and Drug Administration Review Center (CDE) to conduct clinical research in China."

IND • New trial • Oncology • Solid Tumor

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=68 | Recruiting | Sponsor: Pyrotech Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=68 | Not yet recruiting | Sponsor: Pyrotech Therapeutics, Inc.

New P1/2 trial • Oncology • Solid Tumor